Sunday , 20 August 2017

Home » RESOURCES » INVESTING » BioMarin’s stock falls after FDA says it’s not ready to approve NDA for MS drug

BioMarin’s stock falls after FDA says it’s not ready to approve NDA for MS drug

BioMarin Pharmaceutical Inc.’s stock fell 2.5% in premarket trade Thursday, after the biotechnology company said the Food and Drug Administration would not be approving its new drug application (NDA) for its muscular dystrophy treatment Kyndrisa. The FDA said in its “complete response” letter to the NDA that the standard substantial evidence of effectiveness has not been met. BioMarin said it will work with the FDA to determine the next steps it needs to take. The stock has tumbled 19% over the past three months, while the iShares Nasdaq Biotechnology ETF has lost 7.1% and the S&P 500 has slipped 5.2%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

BioMarin’s stock falls after FDA says it’s not ready to approve NDA for MS drug Reviewed by on . BioMarin Pharmaceutical Inc.'s stock fell 2.5% in premarket trade Thursday, after the biotechnology company said the Food and Drug Administration would not be a BioMarin Pharmaceutical Inc.'s stock fell 2.5% in premarket trade Thursday, after the biotechnology company said the Food and Drug Administration would not be a Rating:
scroll to top